Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Citi downgrades Hims & Hers stock citing GLP-1 launch risks

EditorEmilio Ghigini
Published 05/22/2024, 04:52 PM
HIMS
-

On Wednesday, Citi revised its stance on NYSE:HIMS stock, downgrading the company from Buy to Neutral, while simultaneously raising the price target to $20.00 from the previous $16.00. The adjustment follows a recent announcement by Hims & Hers regarding the launch of a new GLP-1 program.

The company's approach to the GLP-1 launch was initially met with concern due to potential regulatory and legal risks. However, after discussions with the management, Citi acknowledged the company's cautious and compliant strategy.

Hims & Hers have partnered with a notable 340B manufacturer for the production of Semaglutide, an active pharmaceutical ingredient (API) similar to that used by Novo Nordisk (NYSE:NVO).

Management assured that the production process for Semaglutide is relatively straightforward and that their manufacturing partner is capable of meeting the anticipated high demand for the product. There are no apparent shortages of API, which supports the program's launch.

Despite these positive aspects, Citi's decision to downgrade comes after the company's stock value increased by 20% following the GLP-1 announcement. This surge added approximately $760 million to Hims & Hers' enterprise value.

According to Citi, this leaves limited potential for further stock appreciation. The firm is now taking a more cautious stance, waiting for additional details on the economics and sustainability of the GLP-1 program before reconsidering its rating.

InvestingPro Insights

Following Citi's recent rating adjustment on Hims & Hers, the InvestingPro platform offers additional insights into the company's financial health and market performance. With a significant market capitalization of $3.77 billion, Hims & Hers stands out in its sector. The company has experienced a notable revenue growth of 55.65% over the last twelve months as of Q1 2024, highlighting a robust upward trajectory in sales. This is further bolstered by a quarterly revenue growth of 45.81% in Q1 2024, signaling sustained momentum.

InvestingPro Tips indicate that analysts are optimistic about the company's future, with net income expected to grow this year and three analysts having revised their earnings upwards for the upcoming period. Additionally, Hims & Hers has demonstrated a strong return over the past week, month, and three months, with a 26.88%, 47.81%, and 85.82% total price return respectively. This performance is indicative of the market's positive reception to the company's strategic initiatives, such as the new GLP-1 program.

For readers interested in a deeper analysis, there are additional InvestingPro Tips available, including insights on the company's debt levels, liquidity, and profitability projections. To access these valuable tips, visit https://www.investing.com/pro/HIMS and remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.